SGI-110 (guadecitabine)

DRUG2 trials

Sponsors

Astex Pharmaceuticals, Inc., National Cancer Institute (NCI)

Conditions

Carcinoma, Renal CellGastrointestinal Stromal TumorsLeukemia, Myeloid, AcuteParagangliomaPheochromocytomaRenal Neoplasms

Phase 2

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

TerminatedNCT03165721

National Cancer Institute (NCI)Carcinoma, Renal Cell, Gastrointestinal Stromal Tumors, Paraganglioma +2

Start: 2017-08-16End: 2020-02-24Updated: 2026-02-18

Phase 3

SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction

CompletedNCT02348489

Astex Pharmaceuticals, Inc.Leukemia, Myeloid, Acute

Start: 2015-03-19End: 2019-06-17Updated: 2024-08-27

Related Papers

P417: GENOMIC LANDSCAPE AND PROGNOSIS IN OLDER ACUTE MYELOID LEUKEMIA PATIENTS NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY

HemaSphere2023-08-011 citations

Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study

Blood Advances2023-06-0520 citations

A phase II trial of the DNA methyl transferase inhibitor, SGI-110 (Guadecitabine), in children and adults with SDH-deficient GIST, pheochromocytoma, and paraganglioma, and HLRCC-associated kidney cancer.

Journal of Clinical Oncology2020-05-205 citations

A phase II trial of the DNA methyl transferase inhibitor, SGI-110 (guadecitabine), in children and adults with wild type GIST, pheochromocytoma and paraganglioma associated with succinate dehydrogenase deficiency and HLRCC-associated kidney cancer.

Journal of Clinical Oncology2018-05-204 citations

Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.

2017-08-24115 citations

Comparison of Efficacy and Safety Results in 103 Treatment-Naïve Acute Myeloid Leukemia (TN-AML) Patients Not Candidates for Intensive Chemotherapy Using 5-Day and 10-Day Regimens of Guadecitabine (SGI-110), a Novel Hypomethylating Agent (HMA)

Blood2015-12-038 citations